Recent Advances in Medications for Reducing Lipid Levels

Dyslipidemia is a major risk factor for atherosclerotic cardiovascular diseases (ASCVD), and effective lipid-lowering therapies are critical for reducing ASCVD risk. This review aims to provide an updated overview of the latest advancements in lipid-lowering therapies, focusing on emerging therapeutic targets and innovative biotechnological approaches that have shown promise in clinical research. Recent years have witnessed significant progress in lipid-lowering therapies beyond traditional statins and ezetimibe. Novel therapeutic targets, such as PCSK9 inhibitors, angiopoietin-like 3 protein inhibitors, APOC3 inhibitors, and omega-3 fatty acids, have demonstrated potent lipid-lowering efficacy. Additionally, advancements in biotechnology have led to the development of innovative agents, including monoclonal antibodies, antisense oligonucleotides (ASOs), small interfering RNA, and cholesterol vaccines, all of which have shown encouraging results in clinical trials. These therapies offer new mechanisms of action and improved efficacy in managing dyslipidemia and reducing ASCVD risk. This article comprehensively reviews the latest clinical research on emerging lipid-lowering targets and cutting-edge therapies, emphasizing their mechanisms, efficacy, and potential impact on dyslipidemia and ASCVD management. The rapid evolution of these therapies highlights a transformative era in cardiovascular disease prevention and treatment, offering hope for improved patient outcomes.